Literature DB >> 10592853

A comparative study of the safety and efficacy of FemCap, a new vaginal barrier contraceptive, and the Ortho All-Flex diaphragm. The FemCap Investigators' Group.

C Mauck1, M Callahan, D H Weiner, R Dominik.   

Abstract

The FemCap is a new silicone rubber barrier contraceptive shaped like a sailor's hat, with a dome that covers the cervix, a rim that fits into the fornices, and a brim that conforms to the vaginal walls around the cervix. It was designed to result in fewer dislodgments and less pressure on the urethra than the cervical cap and diaphragm, respectively, and to require less clinician time for fitting. This was a phase II/III, multicenter, randomized, open-label, parallel group study of 841 women at risk for pregnancy. A subset of 42 women at one site underwent colposcopy. Women were randomized to use the FemCap or Ortho All-Flex contraceptive diaphragm, both with 2% nonoxynol-9 spermicide, for 28 weeks. The objectives were to compare the two devices with regard to their safety and acceptability and to determine whether the probability of pregnancy among FemCap users was no worse than that of the diaphragm (meaning not more than 6 percentage points higher). The 6-month Kaplan-Meier cumulative unadjusted typical use pregnancy probabilities were 13.5% among FemCap users and 7.9% among diaphragm users. The adjusted risk of pregnancy among FemCap users was 1.96 times that among diaphragm users, with an upper 95% confidence limit of 3.01. Clinical equivalence (noninferiority) of the FemCap compared with the diaphragm, as defined in this study, would mean that the true risk of pregnancy among FemCap users was no more than 1.73 times the pregnancy risk of diaphragm users. Because the observed upper 95% confidence limit (and even the point estimate) exceeded 1.73, the probability of pregnancy among FemCap users, compared with that among diaphragm users, did not meet the definition of clinical equivalence used in this study. The FemCap was believed to be safe and was associated with significantly fewer urinary tract infections. More women reported problems with the FemCap with regard to insertion, dislodgement, and especially removal, although their general assessments were positive. The two devices were comparable with regard to safety and acceptability, but a 6-point difference in the true 6-month pregnancy probabilities of the two devices could not be ruled out. Further studies are needed to determine whether design modifications can simplify insertion and removal.

Entities:  

Mesh:

Year:  1999        PMID: 10592853     DOI: 10.1016/s0010-7824(99)00068-2

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  6 in total

1.  FemCap with removal strap: ease of removal, safety and acceptability.

Authors:  Christine K Mauck; Debra H Weiner; Mitchell D Creinin; David F Archer; Jill L Schwartz; Helen C Pymar; Susan A Ballagh; Deborah M Henry; Marianne M Callahan
Journal:  Contraception       Date:  2005-10-19       Impact factor: 3.375

2.  Engineering sperm-binding IgG antibodies for the development of an effective nonhormonal female contraception.

Authors:  Bhawana Shrestha; Alison Schaefer; Yong Zhu; Jamal Saada; Timothy M Jacobs; Elizabeth C Chavez; Stuart S Olmsted; Carlos A Cruz-Teran; Gabriela Baldeon Vaca; Kathleen Vincent; Thomas R Moench; Samuel K Lai
Journal:  Sci Transl Med       Date:  2021-08-11       Impact factor: 17.956

3.  Hexavalent sperm-binding IgG antibody released from vaginal film for development of potent on-demand nonhormonal female contraception.

Authors:  Bhawana Shrestha; Kathleen Vincent; Alison Schaefer; Yong Zhu; Gracie Vargas; Massoud Motamedi; Kelsi Swope; Josh Morton; Carrie Simpson; Henry Pham; Miles B Brennan; Michael H Pauly; Larry Zeitlin; Barry Bratcher; Kevin J Whaley; Thomas R Moench; Samuel K Lai
Journal:  Proc Natl Acad Sci U S A       Date:  2021-11-30       Impact factor: 11.205

4.  Participant characteristics associated with withdrawal from a large randomized trial of spermicide effectiveness.

Authors:  Elizabeth G Raymond; Pai Lien Chen; Bosny Pierre-Louis; Joanne Luoto; Kurt T Barnhart; Lynn Bradley; Mitchell D Creinin; Alfred Poindexter; Livia Wan; Mark Martens; Robert Schenken; Cate F Nicholas; Richard Blackwell
Journal:  BMC Med Res Methodol       Date:  2004-10-01       Impact factor: 4.615

5.  The postcoital test in the development of new vaginal contraceptives†.

Authors:  Christine K Mauck; Kathleen L Vincent
Journal:  Biol Reprod       Date:  2020-08-04       Impact factor: 4.285

Review 6.  Cervical cap versus diaphragm for contraception.

Authors:  M F Gallo; D A Grimes; K F Schulz
Journal:  Cochrane Database Syst Rev       Date:  2002
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.